The effect of the TKIs on non-cancer cells varied from culture to culture, with dabrafenib being effective in both CK8/18+ and CK8/18− cells, crizotinib primarily targeting stromal cells, and nintedanib showing a strong response in stromal cell populations. Here, KRT8 is linked to cancer.